Figure 1. (A): T2, T5-T8 in the spinal cord with slightly longer T2 signal shadow; (B): No patchy abnormal enhancement was observed--图1. (A):T2、T5-T8脊髓内条状稍长T2信号影;(B):未见斑片状异常强化影--
辅助检查:血布氏杆菌凝集试验阳性。脑脊液结果:脑压90 mm H2O,脑脊液布氏杆菌凝集试验阳性,脑脊液测定蛋白质、葡萄糖、氯化物及细胞计数均未见异常,未见寡克隆带。血清MOG抗体检测结果阳性,滴度为1:10,脑脊液MOG抗体检测结果性。其余血液化验都没有发现异常。眼眶MRI增强和颅脑MRI平扫无异常。胸椎MRI平扫显示T2、T5-T8脊髓内条状稍长T2信号影(见
图1(A)
),胸椎MRI增强扫描未见斑片状异常强化影(见
图1(B)
)。双眼OCT显示双侧视乳头水肿。脑干听觉诱发电位显示双耳BAEP异常。体感诱发电位显示上下肢SEP均异常。
治疗方案及预后:入院后给予患者利福平联合盐酸多西环素治疗布氏杆菌病,入院第3天开始给予甲泼尼龙琥珀酸钠激素冲击治疗,入院第5天症状加重,开始加用丙种球蛋白25 g QD进行免疫治疗,并联合头孢曲松钠抗布氏杆菌病治疗,但治疗效果不佳,患者视力下降、肢体麻木无力等症状较入院时进展加重,出院后患者继续在当前医院治疗,同时进行中医理疗促进肢体康复,但治疗效果仍不佳。
References
Borisow, N., Mori, M., Kuwabara, S., Scheel, M. and Paul, F. (2018) Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Frontiers in Neurology, 9, Article 888. >https://doi.org/10.3389/fneur.2018.00888
Chen, H.X., Zhang, Q., Lian, Z.Y., Liu, J., Shi, Z.Y., Miao, X.H., et al. (2017) Muscle Damage in Patients with Neuromyelitis Optica Spectrum Disorder. Neurology Neuroimmunology&Neuroinflammation, 4, e400. >https://doi.org/10.1212/nxi.0000000000000400
Baba, T., Nakashima, I., Kanbayashi, T., Konno, M., Takahashi, T., Fujihara, K., et al. (2009) Narcolepsy as an Initial Manifestation of Neuromyelitis Optica with Antiaquaporin-4 Antibody. Journal of Neurology, 256, 287-288. >https://doi.org/10.1007/s00415-009-0139-4
Uzura, Y., Takeuchi, H., Ashida, S., Fujii, C., Shishido-Hara, Y., Inaba, T., et al. (2022) A Tumefactive Anti-MOG Antibody Associated Disorder Heralding Central Nervous System B-Cell Lymphoma: Case Report on Diagnostic Challenge. Journal of Neuroimmunology, 365, 577823. >https://doi.org/10.1016/j.jneuroim.2022.577823
Hennes, E.M., Baumann, M., Schanda, K., Anlar, B., Bajer-Kornek, B., Blaschek, A., et al. (2017) Prognostic Relevance of MOG Antibodies in Children with an Acquired Demyelinating Syndrome. Neurology, 89, 900-908. >https://doi.org/10.1212/wnl.0000000000004312
Juryńczyk, M., Jacob, A., Fujihara, K. and Palace, J. (2018) Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease: Practical Considerations. Practical Neurology, 19, 187-195. >https://doi.org/10.1136/practneurol-2017-001787
Reindl, M. and Waters, P. (2018) Myelin Oligodendrocyte Glycoprotein Antibodies in Neurological Disease. Nature Reviews Neurology, 15, 89-102. >https://doi.org/10.1038/s41582-018-0112-x
Avila-Calderón, E.D., Lopez-Merino, A., Sriranganathan, N., Boyle, S.M. and Contreras-Rodríguez, A. (2013) A History of the Development Ofbrucellavaccines. BioMed Research International, 2013, Article ID: 743509. >https://doi.org/10.1155/2013/743509
Yagupsky, P., Morata, P. and Colmenero, J.D. (2019) Laboratory Diagnosis of Human Brucellosis. Clinical Microbiology Reviews, 33, e00073-19. >https://doi.org/10.1128/cmr.00073-19
Akdeniz, H., Irmak, H., Anlar, Ö. and Demiröz, A.P. (1998) Central Nervous System Brucellosis: Presentation, Diagnosis and Treatment. Journal of Infection, 36, 297-301. >https://doi.org/10.1016/s0163-4453(98)94279-7
Hou, H., Liu, X. and Peng, Q. (2019) The Advances in Brucellosis Vaccines. Vaccine, 37, 3981-3988. >https://doi.org/10.1016/j.vaccine.2019.05.084